PALB2 variant status in hematological malignancies - a potential therapeutic target?

Leuk Lymphoma. 2019 Jul;60(7):1823-1826. doi: 10.1080/10428194.2018.1551539. Epub 2019 Jan 7.

Authors

Ceri E Oldreive¹, Philip J Byrd¹, Grant S Stewart¹, Alexander J Taylor¹, Sana Farhat¹, Anna Skowronska², Edward Smith¹, Manoj Raghavan¹, Dragana Janic³, Lidija Dokmanovic³, Sam Clokie², Nicholas Davies¹, Marwan Kwok¹, Guy Pratt¹, Shankara Paneesha⁴, Paul Moss⁵, Tatjana Stankovic¹, Malcolm Taylor¹

Affiliations

¹ a Institute of Cancer and Genomic Sciences, University of Birmingham , Birmingham , UK.
² b West Midlands Regional Genetics Laboratory , Birmingham , UK.
³ c School of Medicine, University Children's Hospital , University of Belgrade , Belgrade , Serbia.
⁴ d Heartlands Hospital , Birmingham , UK.
⁵ e Institute of Immunity and Infection, University of Birmingham , Birmingham , UK.

PMID: 30614742
DOI: 10.1080/10428194.2018.1551539

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics*
Fanconi Anemia Complementation Group N Protein / genetics*
Genetic Variation*
Hematologic Neoplasms / genetics*
Hematologic Neoplasms / pathology*
Humans
Prognosis

Substances

Biomarkers, Tumor
Fanconi Anemia Complementation Group N Protein
PALB2 protein, human

Grants and funding